Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase 1/2 15Phase 1 13Phase 3 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 196Other solid neoplasm 6Tumor-Agnostic 5Gynecologic 5Head & Neck 2Gastrointestinal 2CNS 2Genitourinary 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1

Interventions

Fluorouracil 309Oxaliplatin 260Leucovorin 234Capecitabine 198Irinotecan 147Gemcitabine 128Cisplatin 126Bevacizumab 119Radiotherapy 72Paclitaxel 64Folfox protocol 56Cetuximab 56Drug Therapy 46Sorafenib 45Docetaxel 42S 1 (combination) 40Chemotherapy, Adjuvant 38Neoadjuvant Therapy 37pembrolizumab 36130-nm albumin-bound paclitaxel 29Surgical Procedures, Operative 27regorafenib 25lenvatinib 24XELOX 24Radiation 24Panitumumab 24Nivolumab 23atezolizumab 22Carboplatin 22trifluridine tipiracil drug combination 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Pemetrexed × Gastrointestinal × Clear all
NCT03061058 2017-09-15

Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 3 Unknown
240 enrolled
Gastrointestinal

Stomach Neoplasms

NCT00035035 2006-07-19

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

Eli Lilly and Company

Phase 3 Completed
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡